About Bivision
A clinical stage biopharmaceutical company focuses on Targeted Radionuclide Therapy to address unmet medical needs.
Scroll down

Bivision Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel targeted radiopharmaceuticals to address significant unmet medical needs. Bivision has a diversified R&D pipeline cross different stage of drug discovery and development process. Its lead drug candidate JH02, a Lutetium-177 labeled small molecule ligand targeting Prostate Specific Membrane Antigen (PSMA) for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) has been approved by both FDA and CDE and currently is under Phase I/II clinical trial. Since inception, Bivision has built a proprietary technology platform which enables its drug R&D programs to be advanced to clinical stage much fast. Bivision will strive to become a patient-oriented biotech company committed to provide patients with better radiopharmaceuticals which allow more patients to have a better quality of life.

Discovery, development and commercialization of targeted radiopharmaceuticals to address the significant unmet medical needs
Management Team
Dr.Haihua Yu
Co-founder CEO

15 yrs in new drug discovery ; led the development of a molecular imaging CDMO

Ph.D.from Fudan University

Dr.Kevin Wang
Co-founder CTO

2 decades of biotech R&D in targeted radionuclides;3 NDAs, 9 INDs, 15 US patents

Ph.D.from Queen's University

Dr.Eric Wang
Co-founder Med Chem SVP

25 yrs in drug and radiopharmaceuticals R&D; 3 NDAs, 36 US patents

Ph.D.from Univ. of North Texas

Dr.Tony He
Co-founder Biology SVP

Led 30+ drug development projects/programs

Ph.D.from Fudan University

Our History
  • 2021.06


  • 2021.08

    Seed round closed

  • 2021.12

    JH002 PCC confirmed


    since inception of Bivision

  • 2022.05

    Angel round closed

  • 2023.06

    JH002 IND approved by FDA

  • 2023.07

    JH002 IND approved by CDE 24-month since inception of Bivision

  • 2023.12

    JH003/004 PCC confirmed 30-month since inception of Bivision

    JH002 Phasel 1st patient dosed